Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare to Relocate Imaging Research Business to NJ from Canada

NEW YORK, March 10 (GenomeWeb News) - GE Healthcare will relocate Imaging Research, the Ontario-based bioinformatics and screening company it acquired with Amersham, to Piscataway, NJ, later this month, GenomeWeb News has learned.

 

The company, which employed 45 staffers as of December 2003, will formally shut down its St. Catharines, Ontario, facility before the end of the month, according to people familiar with the event. Amersham acquired Imaging Research in 2003, and GE Healthcare bought Amersham one year later.

 

A telephone call placed to Imaging Research was routed to a general company mailbox. The mailbox still identifies the company as Amersham Biosciences Niagara.

 

GE Healthcare did not immediately return a telephone call seeking comment.

 

According to Imaging Research's website, the company's products and services include laboratory-imaging systems and gene expression-analysis software, such as the ArrayVision software for the quantifying gene-expression arrays, and ArrayStat, which analyzes expression array data.

 

The company also sells ultra-high throughput screening platforms, such as LEADseeker, and the IN Cell Analyzer 1000 automated cell-screening system. Imaging Research said "both of these enabling technologies are licensed exclusively to Amersham Biosciences," which was acquired by GE in April 2004.

 

On Imaging Research's website, GE is listed as a USand Canadian distributor for its products. Other countries in which the company's products are sold include  France, Germany, Japan, Korea, the Netherlands, and Taiwan.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.